Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update
Systemic therapy for hepatocellular carcinoma (HCC) has changed markedly since the introduction of the molecular targeted agent sorafenib in 2007. Sorafenib increased the available treatment options for patients with extrahepatic spread and vascular invasion and improved survival in patients with ad...
Main Author: | Masatoshi Kudo |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-11-01
|
Series: | Liver Cancer |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/511001 |
Similar Items
-
Recent Advances in Immunotherapy for Hepatocellular Carcinoma
by: Shigeharu Nakano, et al.
Published: (2020-03-01) -
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
by: Masatoshi Kudo
Published: (2018-10-01) -
The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review
by: Francesca Matilde Schipilliti, et al.
Published: (2021-01-01) -
Immunotherapy Updates in Advanced Hepatocellular Carcinoma
by: Amisha Singh, et al.
Published: (2021-04-01) -
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-10-01)